MRD Connect
  • Saved

Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy - PubMed

Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34646761/

Different factors are used as predictors of unfavorable clinical outcomes in B-Cell Acute Lymphoblastic Leukemia (B-ALL) patients. However, new prognostic markers are needed in order to allow treatment to be...

  • Saved

Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia - PubMed

Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34648216/

The high survival with HR blocks seems favorable compared with other studies. However, the limit of treatment intensification might have been reached as the number of patients dying from leukemia...

  • Saved

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study - PubMed

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34657128/

Chromosomal abnormalities are established prognostic markers in adult ALL. We assessed the prognostic impact of established chromosomal abnormalities and key copy number alterations (CNA) among 652 patients with B-cell precursor...

  • Saved

Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic Leukemia - PubMed

Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic Leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34661158/

Cytogenetics supported by additional molecular analyses and minimal residual disease detection have been successfully combined to improve the outcome of childhood acute lymphoblastic leukemia (ALL). Results from the St. Jude...

  • Saved

Measurable residual disease monitoring of SPAG6, ST18, PRAME, and XAGE1A expression in peripheral blood may detect imminent relapse in childhood acute myeloid leukemia - PubMed

Measurable residual disease monitoring of SPAG6, ST18, PRAME, and XAGE1A expression in peripheral blood may detect imminent relapse in childhood acute myeloid leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34600138/

Overexpressed genes may be applicable for monitoring of measurable residual disease (MRD) in childhood acute myeloid leukemia (AML) patients without a leukemia-specific target. The normal expression of five leukemia-associated genes...